guselkumab
European Commission approves Johnson & Johnson’s Crohn’s disease therapy
May 12, 2025Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation
The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
Janssen reveals positive CHMP opinion, long-term data for psoriasis drug guselkumab
September 19, 2017Manufacturing and Production, Research and Development, Sales and Marketing EMA< CHMP, Janssen, guselkumab, pharma, pharmaceuticals
Janssen has announced that its psoriasis drug guselkumab has been awarded a positive opinion by the EMA’s Committee for Medicinal …
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 6, 2017Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis
Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …
